PDF icon Download PDF
Dtsch Med Wochenschr 2009; 134(15): 740-746
DOI: 10.1055/s-0029-1220224
Übersicht | Review article
Kardiologie, Labormedizin
© Georg Thieme Verlag KG Stuttgart · New York

Biomarker bei Herzinsuffizienz: klinischer Stellenwert belegt?

Biomarkers in heart failure: are they clinically useful?T. Kempf1 , K. C. Wollert1
  • 1Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover
Further Information

Publication History

eingereicht: 16.12.2008

akzeptiert: 12.2.2009

Publication Date:
01 April 2009 (online)

Also available ateRef
   Permissions and Reprints
Preview

Schlüsselwörter

Biomarker - Herzinsuffizienz - natriuretische Peptide - BNP - NT-proBNP - Troponin - GDF-15

Keywords

biomarkers - heart failure - natriuretic peptides - BNP - NT-proBNP - troponin - GDF-15

Literatur

  • 1 Anand I S. Anemia and chronic heart failure implications and treatment options.  J Am Coll Cardiol. 2008;  52 501-511
    Search in Google Scholar
  • 2 Anand I S, Kuskowski M A, Rector T S. et al . Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.  Circulation. 2005;  112 1121-1127
    Search in Google Scholar
  • 3 Anker S D, Doehner W, Rauchhaus M. et al . Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.  Circulation. 2003;  107 1991-1997
    Search in Google Scholar
  • 4 Babuin L, Jaffe A S. Troponin: the biomarker of choice for the detection of cardiac injury.  Can Med Assoc J. 2005;  173 1191-1202
    Search in Google Scholar
  • 5 Braunwald E. Biomarkers in heart failure.  New Engl J Med. 2008;  358 2148-2159
    Search in Google Scholar
  • 6 Bursi F, Weston S A, Redfield M M. et al . Systolic and diastolic heart failure in the community.  JAMA. 2006;  296 2209-2216
    Search in Google Scholar
  • 7 Pfisterer M, Buser P, Rickli H. et al . BNP-guided vs symptom-guided heart failure therapy: the trial of Intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial.  JAMA. 2009;  301 383-392
    Search in Google Scholar
  • 8 Cowie M R, Struthers A D, Wood D A. et al . Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.  Lancet. 1997;  350 1349-1353
    Search in Google Scholar
  • 9 Daniels L B, Maisel A S. Natriuretic peptides.  J Am Coll Cardiol. 2007;  50 2357-2368
    Search in Google Scholar
  • 10 Dickstein K, Cohen-Solal A, Filippatos G. et al . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008.  Eur Heart J. 2008;  29 2388-2442
    Search in Google Scholar
  • 11 Fonarow G C, Adams Jr K F, Abraham W T, Yancy C W, Boscardin W J. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.  JAMA. 2005;  293 572-580
    Search in Google Scholar
  • 12 Forman D E, Butler J, Wang Y. et al . Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.  J Am Coll Cardiol. 2004;  43 61-67
    Search in Google Scholar
  • 13 Gerszten R E, Wang T J. The search for new cardiovascular biomarkers.  Nature. 2008;  451 949-952
    Search in Google Scholar
  • 14 Ginsburg G S, McCarthy J J. Personalized medicine: revolutionizing drug discovery and patient care.  Trends Biotechnol. 2001;  19 491-496
    Search in Google Scholar
  • 15 Goldsmith S R. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.  Am J Cardiol. 2005;  95 14B-23B
    Search in Google Scholar
  • 16 Gustafsson F, Steensgaard-Hansen F, Badskjaer J, Poulsen A H, Corell P, Hildebrandt P. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure.  J Card Fail. 2005;  11 S15-20
    Search in Google Scholar
  • 17 Hare J M, Mangal B, Brown J. et al . Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.  J Am Coll Cardiol. 2008;  51 2301-2309
    Search in Google Scholar
  • 18 Heywood J T, Fonarow G C, Costanzo M R, Mathur V S, Wigneswaran J R, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database.  J Card Fail. 2007;  13 422-430
    Search in Google Scholar
  • 19 Hillege H L, Nitsch D, Pfeffer M A. et al . Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.  Circulation. 2006;  113 671-678
    Search in Google Scholar
  • 20 Hoppe U C, Bohm M, Dietz R. et al . Guidelines for therapy of chronic heart failure.  Z Kardiol. 2005;  94 488-509
    Search in Google Scholar
  • 21 Horwich T B, Fonarow G C, Hamilton M A, MacLellan W R, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.  J Am Coll Cardiol. 2002;  39 1780-1786
    Search in Google Scholar
  • 22 Januzzi Jr J L, Camargo C A, Anwaruddin S. et al . The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.  Am J Cardiol. 2005;  95 948-954
    Search in Google Scholar
  • 23 Jessup M, Brozena S. Heart failure.  New Engl J Med. 2003;  348 2007-2018
    Search in Google Scholar
  • 24 Jourdain P, Jondeau G, Funck F. et al . Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.  J Am Coll Cardiol. 2007;  49 1733-1739
    Search in Google Scholar
  • 25 Kempf T, Eden M, Strelau J. et al . The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury.  Circ Res. 2006;  98 351-360
    Search in Google Scholar
  • 26 Kempf T, von Haehling S, Peter T. et al . Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.  J Am Coll Cardiol. 2007;  50 1054-1060
    Search in Google Scholar
  • 27 Klein L, O’Connor C M, Leimberger J D. et al . Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.  Circulation. 2005;  111 2454-2460
    Search in Google Scholar
  • 28 Konstam M A, Gheorghiade M, Burnett Jr J C. et al . Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.  JAMA. 2007;  297 1319-1331
    Search in Google Scholar
  • 29 Lassus J, Harjola V P, Sund R. et al . Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP.  Eur Heart J. 2007;  28 1841-1847
    Search in Google Scholar
  • 30 Latini R, Masson S, Anand I S. et al . Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.  Circulation. 2007;  116 1242-1249
    Search in Google Scholar
  • 31 Latini R, Masson S, Wong M. et al . Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.  Am J Med. 2006;  119 70 e23-e30
    Search in Google Scholar
  • 32 Lee W H, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.  Circulation. 1986;  73 257-267
    Search in Google Scholar
  • 33 Levy W C, Mozaffarian D, Linker D T. et al . The Seattle Heart Failure Model: prediction of survival in heart failure.  Circulation. 2006;  113 1424-1433
    Search in Google Scholar
  • 34 Maisel A, Hollander J E, Guss D. et al . Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.  J Am Coll Cardiol. 2004;  44 1328-1333
    Search in Google Scholar
  • 35 Maisel A, Mueller C, Adams Jr K. et al . State of the art: using natriuretic peptide levels in clinical practice.  Eur J Heart Fail. 2008;  10 824-839
    Search in Google Scholar
  • 36 Maisel A S, Krishnaswamy P, Nowak R M. et al . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.  New Engl J Med. 2002;  347 161-167
    Search in Google Scholar
  • 37 Mann D L, Bristow M R. Mechanisms and models in heart failure: the biomechanical model and beyond.  Circulation. 2005;  111 2837-2849
    Search in Google Scholar
  • 38 Masson S, Latini R, Anand I S. et al . Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.  Clin Chem. 2006;  52 1528-1538
    Search in Google Scholar
  • 39 Moe G W, Howlett J, Januzzi J L, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study.  Circulation. 2007;  115 3103-3110
    Search in Google Scholar
  • 40 Morrow D A, de Lemos J A. Benchmarks for the assessment of novel cardiovascular biomarkers.  Circulation. 2007;  115 949-952
    Search in Google Scholar
  • 41 Mueller C, Scholer A, Laule-Kilian K. et al . Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.  New Engl J Med. 2004;  350 647-654
    Search in Google Scholar
  • 42 Nickel N, Kempf T, Tapken H. et al . Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension.  Am J Resp Crit Care Med. 2008;  178 534-541
    Search in Google Scholar
  • 43 Pascual-Figal D A, Hurtado-Martinez J A, Redondo B, Antolinos M J, Ruiperez J A, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients.  Eur J Heart Fail. 2007;  9 518-524
    Search in Google Scholar
  • 44 Paulus W J, Tschöpe C, Sanderson J E. et al . How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.  Eur Heart J. 2007;  28 2539-2550
    Search in Google Scholar
  • 45 Peacock W FT, De Marco T, Fonarow G C. et al . Cardiac troponin and outcome in acute heart failure.  New Engl J Med. 2008;  358 2117-2126
    Search in Google Scholar
  • 46 Redfield M M, Rodeheffer R J, Jacobsen S J, Mahoney D W, Bailey K R, Burnett C Jr J. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study.  Circulation. 2004;  109 3176-3181
    Search in Google Scholar
  • 47 Rehman S U, Mueller T, Januzzi L Jr J. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.  J Am Coll Cardiol. 2008;  52 1458-1465
    Search in Google Scholar
  • 48 Schiffrin E L, Lipman M L, Mann J F. Chronic kidney disease: effects on the cardiovascular system.  Circulation. 2007;  116 85-97
    Search in Google Scholar
  • 49 Schlittenhardt D, Schober A, Strelau J. et al . Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions.  Cell Tissue Res. 2004;  318 325-333
    Search in Google Scholar
  • 50 Tang W H, Van Lente F, Shrestha K. et al . Impact of myocardial function on cystatin C measurements in chronic systolic heart failure.  J Card Fail. 2008;  14 394-399
    Search in Google Scholar
  • 51 Vasan R S, Benjamin E J, Larson M G. et al . Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.  JAMA. 2002;  288 1252-1259
    Search in Google Scholar
  • 52 Weinberg E O, Shimpo M, De Keulenaer G W. et al . Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.  Circulation. 2002;  106 2961-2966
    Search in Google Scholar
  • 53 Weinberg E O, Shimpo M, Hurwitz S, Tominaga S, Rouleau J L, Lee R T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker.  Circulation. 2003;  107 721-726
    Search in Google Scholar
  • 54 Wollert K C, Kempf T, Lagerqvist B. et al . Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome.  Circulation. 2007;  116 1540-1548
    Search in Google Scholar
  • 55 Wollert K C, Kempf T, Peter T. et al . Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.  Circulation. 2007;  115 962-971
    Search in Google Scholar
  • 56 Wright S P, Doughty R N, Pearl A. et al . Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial.  J Am Coll Cardiol. 2003;  42 1793-1800
    Search in Google Scholar
  • 57 Xu J, Kimball T R, Lorenz J N. et al . GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation.  Circ Res. 2006;  98 342-350
    Search in Google Scholar

Prof. Dr. med. Kai C. Wollert

Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Phone: 0511/532-4055

Fax: 0511/532-5307

Email: wollert.kai@mh-hannover.de